Finoriq research workspace
Acumen Pharmaceuticals, Inc. (ABOS) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Acumen Pharmaceuticals, Inc. (ABOS).
Company Snapshot
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Company
- Acumen Pharmaceuticals, Inc. (ABOS)
- Ticker
- ABOS
- Market Cap
- $158.5M
- Latest Price
- $2.195
- Industry
- Biotech & Pharma
Acumen Pharmaceuticals, Inc. (ABOS) Recent Insider Transactions
Recent market insider transaction records indexed for Acumen Pharmaceuticals, Inc. (ABOS).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Meisner Derek MChief Legal Officer & Corp Sec | S | Disposed | -$6,813 | 2026-03-06 |
| Meisner Derek MChief Legal Officer & Corp Sec | S | Disposed | -$28,311 | 2026-02-27 |
| Meisner Derek MChief Legal Officer & Corp Sec | S | Disposed | -$8,017 | 2026-01-28 |
| Meisner Derek MChief Legal Officer & Corp Sec | S | Disposed | -$45,263 | 2026-01-26 |
| Meisner Derek MChief Legal Officer & Corp Sec | S | Disposed | -$10,718 | 2026-01-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.